| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 11638,724
- Publication Date: May 02, 2023
- Appl. No: 16/610866
- Application Filed: May 04, 2018
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education (Pittsburgh, PA, US)
- Claim: 1. A method of increasing retinal ganglion cell survival in a subject in need thereof, comprising: selecting a subject in need of increased retinal ganglion cell survival, and locally administering to an eye of the subject a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix, wherein the nanovesicles maintain expression of F4/80 and CD-11b on macrophages in the subject, wherein the nanovesicles comprise lysyl oxidase, and wherein the nanovesicles a) do not express CD63 and CD81, or b) are CD63 lo CD81 lo , thereby increasing retinal ganglion cell survival in the subject.
- Claim: 2. The method of claim 1 , wherein the extracellular matrix is a mammalian extracellular matrix.
- Claim: 3. The method of claim 2 , wherein the mammalian extracellular matrix is a human extracellular matrix.
- Claim: 4. The method of claim 1 , wherein the extracellular matrix is derived from esophageal tissue, urinary bladder, small intestinal submucosa, dermis, umbilical cord, pericardium, cardiac tissue, tumor tissue, or skeletal muscle.
- Claim: 5. The method of claim 1 , wherein the nanovesicles comprise miR-145 and/or miR-181.
- Claim: 6. The method of claim 1 , wherein the nanovesicles are administered intravitreally or subretinally.
- Claim: 7. The method of claim 1 , wherein the nanovesicles are administered repeatedly to the eye of the subject.
- Claim: 8. The method of claim 7 , wherein the nanovesicles are administered weekly, bimonthly or monthly to the subject.
- Claim: 9. The method of claim 1 , wherein the subject has glaucoma.
- Claim: 10. The method of claim 9 , further comprising administering to the subject a therapeutically effective amount of an agent that lowers intraocular pressure.
- Claim: 11. The method of claim 10 , wherein the agent that lowers intraocular pressure is a) a prostaglandin analog, b) a beta-adrenergic blocker, c) an alpha-adrenergic agonist, or d) a cholinergic agonist.
- Claim: 12. The method of claim 1 , wherein the subject has retinal ganglion cell degeneration caused by injury.
- Claim: 13. The method of claim 1 , wherein the subject has retinal ganglion cell degeneration caused by a genetic disorder.
- Claim: 14. The method of claim 1 , wherein the subject has pressure-independent glaucomatous optic neuropathy, ischemic optic neuropathy, inflammatory optic neuropathy, compressive optic neuropathy, or traumatic optic neuropathy.
- Claim: 15. The method of claim 1 , wherein the subject has arteritic ischemic optic neuropathy, arteritic ischemic optic neuropathy associated with giant cell arteritis, nonarteritic ischemic optic neuropathy, infiltrative optic neuropathy, infiltrative optic neuropathy associated with sarcoidosis, infectious optic neuropathy, infectious optic neuropathy associated with syphilis, infectious optic neuropathy associated with Lyme disease, infectious optic neuropathy associated with toxoplasmosis, infectious optic neuropathy associated with herpes zoster, optic neuritis from demyelinating disease, post-radiation optic neuropathy, acrodermatitis enteropathica, hereditary optic neuropathy, hereditary optic neuropathy associated with dominant optic neuropathy, compressive optic neuropathy, compressive optic neuropathy associated with orbital pseudotumor, compressive optic neuropathy associated with thyroid eye disease, autoimmune optic neuropathy, or autoimmune optic neuropathy associated with Lupus.
- Claim: 16. The method of claim 1 , wherein the nanovesicles decrease secretion of a cytokine from microglia and/or astrocytes.
- Claim: 17. The method of claim 16 , wherein the cytokine is IL-1β, IL-6, or TNF-α.
- Patent References Cited: 4902508 February 1990 Badylak et al. ; 4956178 September 1990 Badylak et al. ; 4978668 December 1990 Babbs et al. ; 5007927 April 1991 Badylak et al. ; 5281422 January 1994 Badylak et al. ; 5352463 October 1994 Badylak et al. ; 5354274 December 1994 Badylak et al. ; 5372821 December 1994 Badylak et al. ; 5443505 August 1995 Wong et al. ; 5554389 September 1996 Badylak et al. ; 5573784 November 1996 Badylak et al. ; 5645860 July 1997 Knapp et al. ; 5711969 January 1998 Umesh et al. ; 5753267 May 1998 Badylak et al. ; 5762966 June 1998 Knapp et al. ; 5766242 June 1998 Wong et al. ; 5866414 February 1999 Badylak et al. ; 5869079 February 1999 Wong et al. ; 5955110 September 1999 Patel et al. ; 5997575 December 1999 Whitson et al. ; 6096347 August 2000 Geddes et al. ; 6099567 August 2000 Badylak et al. ; 6126686 October 2000 Badylak et al. ; 6187039 February 2001 Hiles et al. ; 6241981 June 2001 Cobb et al. ; 6251090 June 2001 Avery et al. ; 6299895 October 2001 Hammang et al. ; 6331319 December 2001 Badylak et al. ; 6375989 April 2002 Badylak et al. ; 6413540 July 2002 Yaacobi ; 6416777 July 2002 Yaacobi ; 6485723 November 2002 Badylak et al. ; 6576265 June 2003 Spievack ; 6579538 June 2003 Spievack ; 6696270 February 2004 Badylak et al. ; 6699493 March 2004 Wong et al. ; 6783776 August 2004 Spievack ; 6793939 September 2004 Badylak ; 6849273 February 2005 Spievack ; 6852339 February 2005 Spievack ; 6861074 March 2005 Spievack ; 6887495 May 2005 Spievack ; 6890562 May 2005 Spievack ; 6890563 May 2005 Spievack ; 6890564 May 2005 Spievack ; 6893666 May 2005 Spievack ; 6918396 July 2005 Badylak et al. ; 7776596 August 2010 Badylak ; 7815686 October 2010 Badylak ; 7820634 October 2010 Badylak et al. ; 7919121 April 2011 Badylak et al. ; 8003131 August 2011 Badylak ; 8029774 October 2011 Beckman et al. ; 8084048 December 2011 Badylak ; 8409625 April 2013 Badylak ; 8535719 September 2013 Badylak et al. ; 8647677 February 2014 Badylak ; 9277999 March 2016 Badylak et al. ; 9340602 May 2016 Agrawal et al. ; 9480776 November 2016 Badylak et al. ; 9848987 December 2017 Badylak et al. ; 9861662 January 2018 Badylak ; 10092676 October 2018 Amoroso et al. ; 10286119 May 2019 Badylak et al. ; 10729813 August 2020 Badylak et al. ; 11291688 April 2022 Badylak et al. ; 11389566 July 2022 Ramer et al. ; 11389569 July 2022 Badylak et al. ; 11406736 August 2022 Badylak et al. ; 11413375 August 2022 Badylak et al. ; 20040078076 April 2004 Badylak et al. ; 20040187877 September 2004 Badylak et al. ; 20040191226 September 2004 Badylak ; 20060292227 December 2006 McPherson ; 20070135906 June 2007 Badylak et al. ; 20090053279 February 2009 Badylak et al. ; 20100297212 November 2010 Badylak ; 20110097378 April 2011 Badylak ; 20110165126 July 2011 Badylak et al. ; 20110184439 July 2011 William et al. ; 20140031256 January 2014 Lim ; 20140356331 December 2014 Badylak et al. ; 20180125897 May 2018 Badylak et al. ; 20180200405 July 2018 Badylak et al. ; 20180243473 August 2018 Badylak et al. ; 20200261624 August 2020 Crapo et al. ; 20200360565 November 2020 Badylak et al. ; 20210008251 January 2021 Badylak et al. ; 20210106526 April 2021 Badylak et al. ; 20210137988 May 2021 Badylak et al. ; 20210244396 August 2021 Badylak et al. ; 20210244855 August 2021 Badylak et al. ; 20210260246 August 2021 Badylak et al. ; 20210268148 September 2021 Badylak et al. ; 20220143265 May 2022 Badylak et al. ; 20220249549 August 2022 Badylak et al. ; WO 96/31225 October 1996 ; WO 00/32209 June 2000 ; WO 00/40089 July 2000 ; WO 01/28474 April 2001 ; WO 02/089767 November 2002 ; WO 03/059221 July 2003 ; WO 03/059284 July 2003 ; WO 2005/079844 September 2005 ; WO 2010/099463 September 2010 ; WO 2015/179227 November 2015 ; WO 2017/151862 September 2017 ; WO 2018/161028 September 2018 ; WO 2018/161034 September 2018 ; WO 2018/204848 November 2018 ; WO 2019/213482 November 2019 ; WO 2021/081231 April 2021 ; WO 2021/211885 October 2021 ; WO 2021/217018 October 2021 ; WO 2022/055559 March 2022
- Other References:
- Primary Examiner: Ariani, Kade
- Attorney, Agent or Firm: Klarquist Sparkman, LLP
|
